Laboratory Corporation of America Holdings

NYSE LH

Download Data

Laboratory Corporation of America Holdings Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: 12.65

Laboratory Corporation of America Holdings Enterprise Value to EBITDA (EV/EBITDA) is 12.65 on June 03, 2024, a 23.94% change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Laboratory Corporation of America Holdings 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 13.58 on March 01, 2024, which is 7.35% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Laboratory Corporation of America Holdings 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 9.80 on June 29, 2023, which is -22.58% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Laboratory Corporation of America Holdings average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 12.00.
NYSE: LH

Laboratory Corporation of America Holdings

CEO Mr. Adam H. Schechter
IPO Date March 29, 1990
Location United States
Headquarters 358 South Main Street, Burlington, NC, United States, 27215
Employees 67,000
Sector Healthcare
Industry Diagnostics & research
Description

Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers.

Similar companies

WAT

Waters Corporation

NA

NA

HOLX

Hologic Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email